美国成人哮喘患者全身性糖皮质激素使用的不良后果：一项真实世界分析

数据集获取（Figshare）

• 源站标题：Adverse consequences of systemic corticosteroids use among a broad population of US adults with asthma: a real-world analysis
• DOI：10.6084/m9.figshare.28565025.v1
• 发布日期：2025-03-10
• 文件数：6 个
• 文件总体积：173.69 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Adverse_consequences_of_systemic_corticosteroids_use_among_a_broad_population_of_US_adults_with_asthma_a_real-world_analysis/28565025

命令行下载

curl -L -o "ijme_a_2477877_sm7615.docx" "https://ndownloader.figshare.com/files/52894045"
curl -L -o "ijme_a_2477877_sm7614.docx" "https://ndownloader.figshare.com/files/52894048"
curl -L -o "ijme_a_2477877_sm7613.docx" "https://ndownloader.figshare.com/files/52894051"
curl -L -o "ijme_a_2477877_sm7612.docx" "https://ndownloader.figshare.com/files/52894054"
curl -L -o "ijme_a_2477877_sm7611.docx" "https://ndownloader.figshare.com/files/52894057"
curl -L -o "ijme_a_2477877_sm7610.docx" "https://ndownloader.figshare.com/files/52894060"

文件清单

• ijme_a_2477877_sm7615.docx（19.66 KB）
• ijme_a_2477877_sm7614.docx（23.90 KB）
• ijme_a_2477877_sm7613.docx（67.72 KB）
• ijme_a_2477877_sm7612.docx（17.53 KB）
• ijme_a_2477877_sm7611.docx（26.49 KB）
• ijme_a_2477877_sm7610.docx（18.39 KB）

文件总体积 173.69 KB（源站 API 实测）。

数据说明

Systemic corticosteroids (SCS) are used to manage asthma exacerbations. Among the broad population of patients with asthma, SCS-related risk of adverse events (AEs), health care resource utilization (HCRU), and costs remain unclear.
This retrospective cohort study used the Optum Research Database claims to identify adults with asthma from 1/1/2017 to 6/30/2022. The index date was the earliest SCS claim for SCS users; non-SCS users were randomly selected and adjusted proportionally to SCS users by index year. SCS use was measured during the first 12 months of follow-up. Inverse probability of treatment weighting balanced the two cohorts for selected baseline demographic and clinical characteristics. SCS users were further stratified into low, medium, and high dose sub-cohorts. SCS-related AEs were assessed up to 48 months, while HCRU and costs were assessed during the first 12 months of follow-up. A generalized linear model (GLM) analyzed follow-up costs by SCS exposure.
The 130,739 patients included 55,363 non-SCS users (42.3%), while 75,376 were SCS users stratified into 60,319 low-, 12,235 medium-, and 2,822 high-dose users. The mean age was 49.6 years; 61.8% were female and 68.9% were non-Hispanic White. SCS users had a significantly greater risk of new-onset acute and chronic SCS-related AEs, increasing incrementally with dose exposure (all p p Retrospective administrative claims studies cannot randomize patients and may not capture all patient events.
Among a broad population of adults with asthma, even low doses of SCS were associated with significantly increased risk of new-onset AEs, HCRU, and costs.
Asthma is a respiratory disease characterized by symptoms that can suddenly flare up, resulting in bronchoconstriction that in some cases requires urgent medical attention. Systemic corticosteroids (SCS) have been used for decades to treat these exacerbations. While effective at relieving symptoms, SCS are associated with detrimental effects of their own. Our study examined the adverse events and costs associated with SCS use. We analyzed the health insurance claims of 130,739 adult patients with asthma: 55,363 (42.3%) did not use systemic corticosteroid

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.28565025.v1（source: https://tandf.figshare.com/articles/dataset/Adverse_consequences_of_systemic_corticosteroids_use_among_a_broad_population_of_US_adults_with_asthma_a_real-world_analysis/28565025）。